Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSV01 Injection in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
NCT07246707Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Jan 2026
- Primary completion
- Oct 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KSV01 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Zhejiang University. Primary endpoint: Dose-limiting Toxicity at 28 days. Started Jan 2026; status: recruiting.
02
Drugs
KSV01
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07246707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07246707.